	US 12,421,283 B2
	Compositions and methods for treatment of cytomegalovirus
David E. Anderson, Newton, MA (US); and Anne-Catherine Fluckiger, Saint Genis les Ollières (FR)
Assigned to Variation Biotechnologies Inc., Ottawa (CA)
Filed by Variation Biotechnologies Inc., Ottawa (CA)
Filed on Feb. 11, 2022, as Appl. No. 17/670,052.
Application 17/670,052 is a continuation of application No. 15/683,355, filed on Aug. 22, 2017, granted, now 11,248,026.
Application 15/683,355 is a continuation of application No. 14/357,423, granted, now 9,777,043, issued on Oct. 3, 2017, previously published as PCT/IB2012/002854, filed on Nov. 9, 2012.
Claims priority of provisional application 61/654,157, filed on Jun. 1, 2012.
Claims priority of provisional application 61/558,800, filed on Nov. 11, 2011.
Prior Publication US 2023/0272013 A1, Aug. 31, 2023
Int. Cl. C07K 14/005 (2006.01); A61K 39/00 (2006.01); A61K 39/245 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/245 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C12N 2710/16134 (2013.01); C12N 2740/13023 (2013.01); C12N 2760/20234 (2013.01)]

17 Claims

1. A virus-like particle (VLP) comprising:

a first polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:1; and

a second polypeptide comprising a transmembrane modified gH polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:16.